.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.The Eli Lilly-partnered biotech plan to detail on the Nasdaq under the symbolic representation “BIOA,” depending on to files filed with the Stocks and also Substitution Compensation. The business has certainly not openly shared an anticipated monetary quantity for the offering.The clinical-stage company proclaims lead prospect azelaprag, a by mouth supplied little particle slated to go into phase 2 screening in combination with semaglutide– offered through Novo Nordisk under brand name Wegovy for fat burning– in the first half of upcoming year. Semaglutide is likewise marketed as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is created to blend well with GLP-1 medications, increasing fat burning while maintaining muscular tissue mass. The investigational drug was located to become well-tolerated one of 265 individuals throughout 8 stage 1 trials, depending on to BioAge.Recently, BioAge garnered the help of Lilly to run a test mixing azelaprag along with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetic issues as Mounjaro and Zepbound for weight management. The partners are actually presently administering a stage 2 trial of azelaprag as well as tirzepatide, with topline end results assumed in the 3rd quarter of 2025.The biotech is also intending a blood insulin sensitiveness proof-of-concept test assessing azelaprag as a monotherapy in the first one-half of next year to support prospective evidence growth.
Furthermore, the firm considers to talk to the FDA for authorization in the second fifty percent of 2025 to release human screening for an NLRP3 prevention targeting metabolic diseases and neuroinflammation.BioAge’s foreseed relocate to the public market adheres to a light uptick in considered biotech IPOs coming from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the latest IPO landscape is actually a “combined picture,” along with top quality companies still debuting on the public markets, simply in lessened amounts, depending on to PitchBook.